Since carolacton is able to inhibit both reactions carried out by this enzyme and perturbs cofactor binding, we believe that carolacton, a non-substrate inhibitor, may be used as a tool compound to assess MTHFD2 as an anti-cancer target in the future. Here, MTHFD2 is linked to cancer.